Vaccine Availability Summary (Attachment A)
Oregon State-Supplied (VFC and 317)
Updated February, 2008
The table below provides a summary of the Oregon state-supplied levels for individual vaccines. Follow the links to access information on ACIP recommended modified schedules (where applicable).
If you would like to receive supply updates, and are unsure of whether we have your email address, please notify Mimi Luther, VFC Program Manager, at lydia.m.luther@state.or.us.
Vaccine |
Availability of Vaccine |
Comvax |
Unavailable until fall 2008. |
DTaP |
Sufficient supply to meet demand. |
Hepatitis A |
Due to a manufacturing change with Merck's hepatitis A vaccine, Vaqta®, supplies are extremely limited, and orders for Vaqta® will not be filled. We will automatically substitute GlaxoSmithKline’s hepatitis A vaccine, Havrix®, on all orders. This will remain in effect until Vaqta® is available again, likely to be in 2008. |
Hepatitis B |
Sufficient supply to meet demand. |
HPV |
Sufficient supply to meet demand. |
Hib |
Due to the existing HIB vaccine supply shortage, providers' VFC vaccine requests will be limited to 75 percent of your average monthly use. |
Influenza |
Currently shipping.
|
IPV |
Sufficient supply to meet demand. |
Meningococcal |
Menactra: Currently, sanofi pasteur reports that the supply of MCVH is adequate to resume vaccinating all recommended groups. Those include: 11 - 12 year olds, 15 year old high school freshman and 18 year old college freshman living in dorms.
Note: As of October 4, 2005, the Vaccine Adverse Event Reporting System (VAERS) received five reports of Guillain-Barre syndrome (GBS) in persons after receipt of Menactra (MCV4) vaccination. All reported GBS cases occurred among person aged 17-18 years who were vaccinated during June 10-July 25, 2005 and had symptom onset 14-31 days after MCV4 vaccination. The rate of GBS based on the number of cases reported within 6 weeks of administration of MCV4 is similar to what might have been expected to occur by chance alone. However, the timing of the onset of neurologic symptoms (i.e., within 2-5 weeks of vaccination) is of concern. FDA and CDC are requesting that providers or other persons with knowledge of possible cases of GBS (or clinically significant adverse events) occurring after vaccination with MCV4 report them to VAERS. Reports of GBS should be submitted to VAERS at http://www.vaers.hhs.gov or by telephone at 1-800-822-7967.
Click here for more information on MCV and GBS.
Menomune: Sanofi Pasteur has instituted an inventory management protocol. Shipping is restricted at this time. |
MMR |
Sufficient supply to meet demand. |
MMRV |
Currently unavailable through 2008. |
PCV7 |
Sufficient supply to meet demand. |
Pediarix |
Sufficient supply to meet demand. |
Rotateq |
Sufficient supply to meet demand. |
Td |
Sufficient supply to meet demand.
|
Tdap |
Sufficient supply to meet demand. |
Varicella |
Varicella is currently taking 15-20 business days to ship. (At least four weeks.) Timeliness expected to improve in early 2008. |
|